Promising
Glatiramer acetate: slow disability worsening in relapsing MS
relapsing MS · Glatiramer acetate
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 5
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 53
Deciding trials (phase 2): 1 met, 0 did not.
Other linked trials: 4
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2012 · Placebo-controlled · MSFT-NCT01569451
Other linked trials: 4
These linked trials do not set the status.
- Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessNo result found
Phase 4 · 1994 · Not randomised
- TREAT-MSResult in a paper, not read yet
Phase not applicable · 2018 · Not randomised
Phase not applicable · 2006 · Not randomised
- Treatment of Multiple Sclerosis With Copaxone and AlbuterolResult in a paper, not read yet
Phase not applicable · 2001 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Promising
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error